Michael-John Devlin

766 citations
11 papers · 441 · 1 hit paper · h-index 4

Impact in

Papers in

    • Ovarian cancer diagnosis and treatment 6
    • PARP inhibition in cancer therapy 2
    • Cancer Immunotherapy and Biomarkers 2
    • Lung Cancer Research Studies 1

Michael-John Devlin

9 papers receiving 435 citations

Michael-John Devlin's Hit Papers

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial 2019 · 312 citations
3120+2+4Years since publication100200300

Peers

Michael-John Devlin
Comparison fields: 5 of 35
  • Obstetrics and Gynecology 118
  • Oncology 210
  • Reproductive Medicine 49
  • Immunology 100
  • Otorhinolaryngology 19
Replace Carsten Golletz with:
Carsten Golletz Germany
Marit Scheistrøen Norway
T Sonoda Japan
A.A.M. van der Wurff Netherlands
Zhongmin Maxwell Wang China
P. Dominick Sanders United States
Michaela Bártů Czechia
Maria M. Rubinstein United States
Mark Crozier United States
Meilian Dong China
Michael-John Devlin relative to Carsten Golletz Germany Carsten Golletz's profile →
Citations per field
00.5×3.2×
Carsten Golletz · 1×
Citations per year

Countries citing papers authored by Michael-John Devlin

Since Specialization
Citations

This map shows the geographic impact of Michael-John Devlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael-John Devlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael-John Devlin more than expected).

Fields of papers citing papers by Michael-John Devlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael-John Devlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael-John Devlin. The network helps show where Michael-John Devlin may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael-John Devlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael-John Devlin Line = papers co-authored together Michael-John Devlin links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
Hit paper breakdown →
2019312
2 201888
3 202223
4 202510
5 20222
6 20232
7 20182
8 20241
9 20171
10 20230
11 20180

About Michael-John Devlin

Michael-John Devlin is a scholar working on Reproductive Medicine, Oncology, Cancer Research, Obstetrics and Gynecology and Molecular Biology, having authored 11 papers that have together received 441 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (6 papers), Endometrial and Cervical Cancer Treatments (2 papers), PARP inhibition in cancer therapy (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Genomics and Diagnostics (2 papers), Lung Cancer Research Studies (1 paper), Lung Cancer Treatments and Mutations (1 paper) and Cancer, Lipids, and Metabolism (1 paper). The work is most often cited by research in Obstetrics and Gynecology (118 citations), Oncology (210 citations), Reproductive Medicine (49 citations), Immunology (100 citations) and Otorhinolaryngology (19 citations). Michael-John Devlin has collaborated with scholars based in United Kingdom, Switzerland and United States. Frequent co-authors include Martin Förster, Kathleen N. Moore, T.R. Jeffry Evans, Jean‐Pierre Delord, Valentina Boni, José M. López-Picazo, Tian Chen, R. Wendel Naumann, Junchen Gu and Tim Meyer. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Gynecological Cancer, Frontiers in Oncology, Cancers and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact